Navigation Links
Angiotech and Symphony Medical Announce Licensing Agreement
Date:1/17/2008

lation device. The concept is protected by a number of patents which are currently pending.

"We are excited about the opportunity to work with Angiotech's biomaterial to address a large unmet clinical need in POAF. According to numerous clinical studies, on average, 40 percent of patients who undergo CABG and coronary valve surgeries develop atrial fibrillation. Based on the success of our preclinical animal model, we have already received EU and Institutional Review Board approval for our 60 patient multi-center 'randomized safety study' in Germany and expect to begin enrolling patients in the first quarter of 2008," said Raymond W. Cohen, CEO of Symphony.

Under the terms of the agreement, Angiotech has been granted an equity position in Symphony Medical in exchange for the exclusive license of Angiotech's technology in the field of POAF. In addition, Angiotech will receive a royalty on end-user product sales should the product receive regulatory approval and is commercialized.

About Post-Operative Atrial Fibrillation (AF)(1)

Atrial fibrillation is a common arrhythmia following open heart surgery that is associated with increased morbidity and mortality. Patients who develop postoperative atrial fibrillation are more likely to have other postoperative complications such as peri-operative MI, CHF and respiratory failure(2). Postoperative atrial fibrillation is associated with longer ICU and hospital stays and consequently, the economic cost can be considerable(3).

About Angiotech

Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and medical device company with over 1,600 dedicated employees. Angiotech discovers, develops and markets innovative treatment solutions for diseases or complications associated with medical device implants, surgical interventions and acute injury. To find out more about Angiotech (NASDAQ: ANPI, TSX: ANP), please visit http://www.ang
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
2. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
3. Angiotech to participate in RBC 2007 Healthcare Conference
4. Angiotech to participate in Bank of America 2007 Credit Conference
5. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
6. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
7. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
8. Angiotech to participate in UBS Global Life Sciences Conference
9. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
10. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
11. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... SAN DIEGO and BETHESDA, Md. ... they are joining together with two institutes from the ... more reliable tools for bringing safer, more effective treatments ... with the National Center for Advancing Translational Sciences (NCATS) ...
(Date:1/14/2014)... , Jan. 14, 2014  RXi Pharmaceuticals Corporation ... developing and commercializing innovative therapies addressing major unmet ... it received the Notice of Allowance from the ... unique self-delivering RNAi compounds (sd-rxRNA®), for the treatment ...
(Date:1/14/2014)... 13, 2014 Bob Hainsey, a semiconductor ... 20 years in the industry, has joined SPIE, ... will serve as the society’s Science and Technology Strategist. ... SPIE as our Technology Strategist, further strengthening the technical ...
(Date:1/14/2014)... 2014 Independent publisher Bitingduck Press, with ... Canada, has big ideas for 2014 in production and ... are to produce high-quality, low-cost, DRM-free ebooks and to ... , The first major development will be bookstore ...
Breaking Biology Technology:Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2Bitingduck Press Looks Forward to 2014 With Multimedia E-books 2
... decades as a manufacturing state, Ohio is positioning itself to ... jobs market. A recent Forbes article ranked Columbus, ... optimistic outlooks for other major Ohio cities. The magazine credits ... home to major research universities. Another contributing ...
... and TORONTO, Dec. 19, 2011 Generex Biotechnology ... scheduled to air a segment on the immunotherapeutic ... subsidiary, Antigen Express, Inc.  The segment is scheduled ... PST) today, Monday, December 19, 2011 (see promo ...
... Inc. announced today that it has entered into ... Biotech, Inc.  The agreement is based on Metamark,s ... specific proprietary cancer targets demonstrated to play a ... (Prognosis Determinants™). The collaboration will focus on the ...
Cached Biology Technology:Ohio's Bioscience Industry Effort Paying Off With Increase in Graduates and Accolades for the State 2Ohio's Bioscience Industry Effort Paying Off With Increase in Graduates and Accolades for the State 3Ohio's Bioscience Industry Effort Paying Off With Increase in Graduates and Accolades for the State 4Breast Cancer Vaccine Being Developed by Generex Subsidiary Antigen Express to be Featured on Bloomberg Television Today 2Breast Cancer Vaccine Being Developed by Generex Subsidiary Antigen Express to be Featured on Bloomberg Television Today 3Breast Cancer Vaccine Being Developed by Generex Subsidiary Antigen Express to be Featured on Bloomberg Television Today 4Metamark Genetics Signs Collaboration Agreement on Novel Therapeutic Targets with Janssen Biotech 2
(Date:4/23/2014)... their mid-thirties and forties, face a devastating prognosis: ... decades. "Mutant" protein clusters, long blamed for the ... primary focus of therapies in development by pharmaceutical ... Gerardo Lederkremer and Dr. Julia Leitman of Tel ... in collaboration with Prof. Ulrich Hartl of the ...
(Date:4/23/2014)... Scarborough research shows that male black widow spiders prefer ... rare example of mate preference by male spiders. ... MacLeod and Maydianne Andrade, a professor in UTSC,s Department ... and the wild that males overwhelmingly chose to mate ... widows can tell whether a potential mate is well-fed ...
(Date:4/23/2014)... the source of a unique rhythmic sound, recorded for ... is the Antarctic minke whale ( Balaenoptera bonaerensis ). ... 1960s who thought it sounded like a duck, the ... the Southern Ocean, but its source has remained a ... team of researchers deployed acoustic tags on two Antarctic ...
Breaking Biology News(10 mins):On the defensive 2On the defensive 3Picky male black widow spiders prefer well-fed virgins 2Scientists identify source of mysterious sound in the Southern Ocean 2Scientists identify source of mysterious sound in the Southern Ocean 3
... has a photo of a cornfield and a big photovoltaic ... Washington University in St. Louis. "When I give talks I ... the audience votes overwhelmingly in favor of photosynthesis. " ... (below) is the point of departure for a provocative article ...
... trials prove successful, a new discovery published in ... a major scientific leap toward human tissue regeneration and ... provide evidence to support a major paradigm shift in ... to a graft before implantation are the building blocks ...
... Cancer studies from Mercer University (Ga.) headline groundbreaking ... of Pharmaceutical Scientists, (AAPS) National Biotechnology Conference (NBC). The ... at the Hilton San Francisco Union Square. ... Cervical cancer is the second most common ...
Cached Biology News:Turning plants into power houses 2Turning plants into power houses 3Turning plants into power houses 4Turning plants into power houses 5Turning plants into power houses 6Yale scientists discover new method for engineering human tissue regeneration 2AAPS national biotechnology conference to highlight breakthrough cancer treatments 2
Lyophilized solid. Suitable for evaluating functional activity of human complement components and for other research requiring a high level of hemolytic activity. ...
... ChipWriter Pro system, 220-240 V, uses floating ... oligonucleotides, carbohydrates, lipids, and other biomolecules onto ... This system can generate high-density arrays with ... or greater than 57,000 spots per membrane ...
... ChipWriter Pro systems are high-precision microarrayers ... other biological samples. VersArray ChipWriter Pro ... spot density, and reproducibility to deliver ... of substrates. Their modular component design ...
... Ciphergen's ProteinChip arrays have been ... from biological samples. A variety of ... of proteins according to their unique ... different spots, allowing side-by-side sample comparison, ...
Biology Products: